Bowen, J., Alpar, H.O., Phillpotts, R. and Brown, M.R.W. (1992) Mucosal delivery of herpes simplex virus vaccine. Research in Virology, 143 . pp. 269-278. 10.1016/S0923-2516(06)80115-9.
Full text not available from this repository.
Mucosal delivery of herpes simplex virus vaccine Vaccination antiherpétique par voie muqueuse This article is not included in your organization's subscription. However, you may be able to access this article under your organization's agreement with Elsevier. J.C. Bowen(1), (**), H.O. Alpar(1), , R. Phillpotts(2), (***) and M.R.W. Brown(1) (1)Pharmaceutical Sciences Institute, The Department of Pharmaceutical Sciences, Aston University, Aston Triangle, Birmingham B4 7ET (UK) (2)Public Health Laboratory Service, Centre for Applied Microbiology and Research, Porton Down, Salisbury SP4 OJG (UK) Received 20 January 1992; accepted 25 May 1992. Available online 22 September 2007. Summary The mucosal route for the production of mucosal and systemic herpes simplex virus (HSV) antibodies was investigated using HSV1 subunit vaccine administered to guinea pigs. Groups of test animals (n=13) were dosed, nasally or vaginally and compared with those injected subcutaneously (s.c.). The vaccines, in aqueous or gel form, were administered 5 and 3 weeks prior to vaginal challenge with HSV2 suspension. Control infected and non-infected animals were included for comparison. Animals which were vaccinated s.c. were shown to respond to subsequent infection with HSV by the production of serum HSV-specific IgG (and IgA) but negligible amounts of vaginal IgG and IgA. Control non-infected and infected-only groups produced none and only a small amount of vaginal HSV-specific antibodies, respectively. Substantial protection against HSV2 infection of the female guinea pig genital tract was provided by s.c. immunization with HSV vaccine. Protection was evaluated in terms of the reduction of histopathological lesions and clinical signs in vaccinated and control animals. The serum humoral response to nasal delivery in phosphate-buffered saline was comparable, and was superior for vaginal washes to that of parenteral vaccination. The nasally delivered free antigen gave significant (p ≤ 0.05) reduction in the severity of the disease and higher levels of specific serum and vaginal immunoglobulin antibodies to HSV when compared with non-immunized infected-only controls, probably due to uptake of anti-genically intact protein. Vaginal gel treatment slightly reduced the severity of the illness and gave higher humoral responses than those induced by vaginally delivered free antigen. Findings also indicate that these mucosal immune responses were produced at a site distant from the site of vaccination, suggesting a common immunological system. Le dosage des IgA et IgG sériques et locaux et l'épreuve de protection des cobayes ont permis d'observer une bonne efficience de l'administration vaginale ou nasale du vaccin antiherpétique, efficience en relation avec des adjuvants sous forme de gel. Ces résultats montrent en particulier que la réponse immunitaire locale dépasse le site d'administration «permuqueuse du vaccin.
|Uncontrolled Keywords:||Herpes simplex, sIgA, Vaccine, Adjuvant, Mucosal delivery; Nasal and vaginal routes, Gels, Guinea pig, Protection, Clinical scores, IgA, IgG|
|Departments, units and centres:||Department of Pharmaceutics > Department of Pharmaceutics|
|Journal or Publication Title:||Research in Virology|
|Deposited By:||Library Staff|
|Deposited On:||20 May 2011 14:55|
|Last Modified:||20 May 2011 14:55|
Item downloaded times since 20 May 2011 14:55.
Repository Staff Only: Item control page
School of Pharmacy Staff Only: Edit a copy to replace this item